top of page
Studies recruiting patients with Alport Syndrome
​Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
Site PI: Dr. Lesley Inker
Contact: lesley.inker@tuftsmedicine.org
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
Site PI: Dr. Lesley Inker
Contact: lesley.inker@tuftsmedicine.org
bottom of page